Stephen Clarke
Stephen Clarke
Professor of Medicine, University of Sydney and Medical Oncologist, RNSH and Genesis Care
Verified email at
Cited by
Cited by
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
LB Saltz, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
Journal of clinical oncology 26 (12), 2013-2019, 2008
The systemic inflammation-based neutrophil–lymphocyte ratio: experience in patients with cancer
GJK Guthrie, KA Charles, CSD Roxburgh, PG Horgan, DC McMillan, ...
Critical reviews in oncology/hematology 88 (1), 218-230, 2013
Cancer-related inflammation and treatment effectiveness
CI Diakos, KA Charles, DC McMillan, SJ Clarke
The Lancet Oncology 15 (11), e493-e503, 2014
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer
J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
Journal of clinical oncology 26 (12), 2006-2012, 2008
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ...
The lancet oncology 13 (12), 1225-1233, 2012
Clinical pharmacokinetics of docetaxel
SJ Clarke, LP Rivory
Clinical pharmacokinetics 36 (2), 99-114, 1999
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer
W Chua, KA Charles, VE Baracos, SJ Clarke
British journal of cancer 104 (8), 1288-1295, 2011
Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer
ET Morgan, KB Goralski, M Piquette-Miller, KW Renton, GR Robertson, ...
Drug Metabolism and Disposition 36 (2), 205-216, 2008
A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer
MJ Proctor, DC McMillan, DS Morrison, CD Fletcher, PG Horgan, ...
British journal of cancer 107 (4), 695-699, 2012
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
N van Zandwijk, N Pavlakis, SC Kao, A Linton, MJ Boyer, S Clarke, ...
The Lancet Oncology 18 (10), 1386-1396, 2017
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy
SCH Kao, N Pavlakis, R Harvie, JL Vardy, MJ Boyer, N van Zandwijk, ...
Clinical cancer research 16 (23), 5805-5813, 2010
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results
J Cassidy, S Clarke, E Díaz-Rubio, W Scheithauer, A Figer, R Wong, ...
British journal of cancer 105 (1), 58-64, 2011
Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial
B Oh, P Butow, B Mullan, S Clarke, P Beale, N Pavlakis, E Kothe, L Lam, ...
Annals of Oncology 21 (3), 608-614, 2010
Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review
EL Davis, B Oh, PN Butow, BA Mullan, S Clarke
The oncologist 17 (11), 1475, 2012
Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy
KA Slaviero, SJ Clarke, LP Rivory
The lancet oncology 4 (4), 224-232, 2003
The relationship between available support, unmet needs and caregiver burden in patients with advanced cancer and their carers
L Sharpe, P Butow, C Smith, D McConnell, S Clarke
Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2005
Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea
R Sharma, P Tobin, SJ Clarke
The lancet oncology 6 (2), 93-102, 2005
Potential regional differences for the tolerability profiles of fluoropyrimidines
DG Haller, J Cassidy, SJ Clarke, D Cunningham, E Van Cutsem, PM Hoff, ...
Journal of Clinical Oncology 26 (13), 2118-2123, 2008
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE …
HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ...
The Lancet Oncology 18 (9), 1159-1171, 2017
Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response
LP Rivory, KA Slaviero, SJ Clarke
British journal of cancer 87 (3), 277-280, 2002
The system can't perform the operation now. Try again later.
Articles 1–20